8-K: Renalytix Secures $11.8 Million in Funding, Restructures Debt, and Plans Nasdaq Delisting

Renalytix has successfully raised $11.8 million through a placing and subscription, restructured its debt, and announced plans to delist from Nasdaq to move to the OTCQX market.

Summary

• Renalytix has raised $11.8 million through a placing and subscription of new ordinary shares at 9 pence per share.
• The company is restructuring its existing debt, including a convertible bond and accounts payable, to reduce monthly cash burn.
• A portion of the convertible bond, approximately $2.75 million, will be converted into equity at the issue price.
• The remaining balance of the convertible bond will be restructured into a new unsecured convertible bond.
• An accounts payable balance of approximately $850,000 will be partially converted to equity and a long-term unsecured note.
• The company is delisting from Nasdaq and plans to have its American Depositary Shares (ADS) quoted on the OTCQX Marketplace.
• The company expects to reduce its monthly cash burn to $560,000 or less by the end of FY25.
• The net proceeds from the fundraise will be used for sales and marketing, EHR integration development, and general working capital.
• The company estimates revenue of approximately $3.2 million in FY25, $8.5 million in FY26 and $17.5 million in FY27.
• The company expects to reach profitability and cash flow break-even in approximately two years.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has secured significant funding and restructured its debt, the financial results for FY24 are poor, and the company is delisting from Nasdaq. The future outlook is positive but relies on achieving ambitious revenue targets.

Positives

• The successful fundraise of $11.8 million provides the company with necessary capital.
• Debt restructuring significantly reduces monthly cash burn and future obligations.
• Moving to OTCQX is expected to result in substantial cost savings.
• The company is demonstrating quarter-over-quarter revenue growth and repeat doctor test ordering.
• The company has a new leadership team with a track record of commercial success.
• The company has a revamped sales and customer service strategy to sustain new doctor on-boarding and retention.
• The company has a significant expansion of patient access to testing sites.
• The company has a major customer launch to approximately 10,000 patients and 140 new ordering doctors starting in September 2024.

Negatives

• The company reported a loss before tax of $44.9 million for FY24.
• The company has negative net liabilities of $8.5 million as of June 30, 2024.
• The company has a history of losses and negative cash flow.
• The company has a history of needing to raise capital to continue operations.

Risks

• The company's future revenue projections are based on assumptions and may not be achieved.
• The company's ability to reach profitability and cash flow break-even in two years is not guaranteed.
• The company's success depends on the continued adoption of its KidneyIntelX test.
• The company's delisting from Nasdaq may impact investor perception.
• The company's ability to maintain its listing on the OTCQX is not guaranteed.
• The company's ability to obtain shareholder approval for the issuance of additional shares is not guaranteed.

Future Outlook

The company expects to reach profitability and cash flow break-even in approximately two years, with projected revenue of $17.5 million in FY27. The company also expects to reduce its monthly cash burn to $560,000 or less by the end of FY25.

Management Comments

• James McCullough, CEO of Renalytix, stated that the strong demand for the fundraise supports the view that Renalytix offers investors unique access to a world-leading kidney prognostic test.
• James McCullough, CEO of Renalytix, stated that the company now has a strong cash and balance sheet position, has taken positive actions to substantially reduce its monthly cash burn, and is delivering quarter-on-quarter growth in orders, whilst also supporting a new customer launch.

Industry Context

The announcement reflects a trend in the healthcare industry towards value-based care and the use of AI-enabled diagnostics. The company's focus on kidney disease aligns with the growing need for early detection and management of chronic conditions. The move to OTCQX is a common strategy for companies seeking to reduce listing costs.

Comparison to Industry Standards

• Renalytix's KidneyIntelX test is the first and only FDA-authorized prognostic test for early-stage CKD risk assessment in T2D patients, setting it apart from competitors.
• The company's Medicare reimbursement of $950 per test is a significant advantage compared to other diagnostic tests.
• The company's focus on EHR integration aligns with industry trends towards digital health solutions.
• The company's move to OTCQX is similar to other companies seeking to reduce listing costs, such as those that have moved from the Nasdaq to the OTC markets.
• The company's projected revenue growth is ambitious but achievable given the market opportunity and the company's unique position.

Management Changes

Related Party Transactions

• James McCullough, Christopher Mills, Catherine Coste, and Fergus Fleming, being Directors of the Company, have subscribed for certain Placing Shares.
• Mount Sinai, being a Substantial Shareholder of the Company, has also subscribed for certain Subscription Shares.

Stakeholder Impact

• Shareholders will be impacted by the dilution of their ownership due to the issuance of new shares.
• Shareholders will be impacted by the delisting from Nasdaq and move to OTCQX.
• Employees may be impacted by the restructuring and cost-cutting measures.
• Customers may benefit from the company's focus on sales and marketing and improved customer service.
• Creditors will be impacted by the debt restructuring and conversion to equity.

Next Steps

• The company will hold a General Meeting on or around 31 October 2024 to seek shareholder approval for the issuance of additional shares.
• The company will file a Form 25 with the SEC on or about 7 October 2024 to effect the voluntary delisting of its ADSs from Nasdaq.
• The company will have its ADSs quoted on the OTCQX Marketplace.
• The company will continue to focus on sales and marketing efforts to drive revenue growth.
• The company will continue to develop EHR integrations with new health systems.

Key Dates

Keywords

Renalytix, KidneyIntelX, Fundraising, Debt Restructuring, Nasdaq Delisting, OTCQX, EHR Integration, Bioprognosis, Kidney Disease, Artificial Intelligence, In Vitro Diagnostics